Free shipping on all orders over $ 500

Glofitamab

Cat. No. M25012

All AbMole products are for research use only, cannot be used for human consumption.

Glofitamab Structure
Synonym:

RO7082859

Price and Availability

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.


Quality Control & Documentation
Biological Activity

Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma.

Chemical Information
CAS Number 2229047-91-8
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Michael J Dickinson, et al. N Engl J Med. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

[2] Vera Rentsch, et al. Cancers (Basel). Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy

[3] Ann-Marie E Bröske, et al. Blood Adv. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma

[4] Adrian Minson, et al. Leuk Lymphoma. Glofitamab CD20-TCB bispecific antibody

[5] Martin Hutchings, et al. J Clin Oncol. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Related CD20 Products
Epcoritamab

Epcoritamab is a novel bispecific IgG1k/λ antibody targeting CD3 and CD20 that activates T cells and directs them to kill malignant CD20+ B cells.Epcoritamab has antitumor activity and may be used in studies related to RR diffuse large B-cell lymphoma (DLBCL).

Zebituzumab

Zebituzumab (zebituzumab) is a recombinant human-mouse chimeric anti-CD20 monoclonal antibody that can be used in studies related to CD20-positive diffuse large B-cell lymphoma.

Veltuzumab

Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL).

Divozilimab

Divozilimab (BCD-132) is a humanized anti-CD20 IgG1ҡ monoclonal antibody for use in studies related to multiple sclerosis.

Zuberitamab

Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma.

  Catalog
Abmole Inhibitor Catalog




Keywords: Glofitamab, RO7082859 supplier, CD20, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.